Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABSI vs ABCL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABCL Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

ABCL Overall Winner 6-Pillar Tally: ABSI 0 – 5 ABCL (1 Tie) Matrix Metrics: ABSI 2 – 8 ABCL

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Absci Corporation (ABSI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABSI carries a Unified Composite Score of 37.5/100 (SELL) at $7.72 (N/M Forward P/E, -9108.3% operating margin), whereas ABCL carries 60.7/100 (BUY) at $11.19 (27.6x Forward P/E, -1550.0% operating margin).

  • Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (60.7/100 BUY vs. ABSI 37.5/100 SELL) and 2.31β · 87% Vol risk profile, whereas ABSI leads top-line expansion (-19.6% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ABSI is currently in a Breakdown options structure phase (RSI 39.3); meanwhile ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 44.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABSI vs ABCL
ABSI NASDAQ
Absci Corporation Common Stock
Services-Commercial Physical & Biological Research
$7.72
-8.58% 1D
Market Cap $1.6B
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 3.31β · 126% Vol
Unified Composite Score
37.5 / 100 SELL
Tech 27.0 Fund 51.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 39.3 · SMA20: $9.94 · SMA50: $9.63
ABCL NASDAQ Head-to-Head Winner
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.19
-2.65% 1D
Market Cap $3.8B
TTM Revenue $66M
Forward P/E 27.6x
Beta / 30D Vol 2.31β · 87% Vol
Unified Composite Score
60.7 / 100 BUY
Tech 52.0 Fund 59.0 Flow 67.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 44
RSI-14: 44.2 · SMA20: $12.05 · SMA50: $12.33

6-Pillar Scorecard Institutional Category Breakdown (ABSI 0 – 5 ABCL)

Columns: Metric · ABSI · ABCL
1. Valuation Multiples ABCL
Forward P/E N/M 27.6x
Trailing P/E N/M 27.6x
PEG Ratio N/M N/M
EV / Revenue N/M 56.9x
2. Growth & Scale ABCL
Revenue Growth (YoY) -19.6% -76.3%
Earnings Growth (YoY) +0.0% +45.9%
TTM Revenue (USD) $1.5M $66M
Market Cap $1.6B $3.8B
3. Profitability & Quality ABCL
Gross Margin N/A N/A
Operating Margin -9108.3% -1550.0%
Net Profit Margin 0.0% -248.8%
Return on Equity (ROE) -58.6% -17.3%
4. Balance Sheet & Cash Flow ABCL
Cash Generation (TTM) -$112M -$33M
Cash Flow Margin N/A -49.6%
Net Cash / Leverage $10M Net Cash $30M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABCL
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 169.1% (15th %ile) 80.8% (25th %ile)
Put/Call OI Skew 0.57x (Call-Skewed) 0.23x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABSI (2) vs ABCL (8)
Institutional Metric ABSI ABCL Criterion Row Edge
Market Capitalization
Scale
$1.6B $3.8B Larger Scale ABCL
Trailing P/E Ratio
Valuation
N/M 27.6x Lower Multiple ABCL
Forward P/E Ratio
Valuation
N/M 27.6x Lower Multiple ABCL
Revenue Growth (YoY)
Growth
-19.6% -76.3% Higher Growth ABSI
Operating Margin (TTM)
Profitability
-9108.3% -1550.0% Higher Margin ABCL
Net Profit Margin
Profitability
0.0% -248.8% Higher Margin ABSI
Return on Equity (ROE)
Capital Efficiency
-58.6% -17.3% Higher ROE ABCL
52-Week Range Position
Momentum
53% ($2–$13) 69% ($3–$15) Stronger Trend ABCL
Beta / 30D Volatility
Risk Regime
3.31β · 126% Vol 2.31β · 87% Vol Lower Realized Risk ABCL
Unified Institutional Score
Composite Signal
37.5 / 100 (SELL) 60.7 / 100 (BUY) Higher Composite ABCL
Trailing 12M Revenue (USD)
Operating Scale
$1.5M $66M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 56.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$112M ($10M Net Cash) -$33M ($30M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABCL +1.15 pp
ABSI: -6.36% · ABCL: -5.21%
3M Horizon ABCL +13.29 pp
ABSI: -12.71% · ABCL: +0.58%
6M Horizon ABCL +112.65 pp
ABSI: +56.22% · ABCL: +168.87%
1Y Horizon ABCL +16.37 pp
ABSI: +192.61% · ABCL: +208.98%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ABSI Revenue ABCL Revenue ABSI Op. Margin ABCL Op. Margin Margin Leader
FY2019 N/A $10M N/A -35.5% ABCL
FY2020 $0M $230M -278.3% 66.9% ABCL
FY2021 $0M $380M -1573.4% 54.5% ABCL
FY2022 $10M $490M -1857.5% 44.6% ABCL
FY2023 $10M $40M -2020.2% -623.8% ABCL
FY2024 $0M $30M -2401.6% -1091.7% ABCL
FY2025 $0M $80M -4297.0% -289.0% ABCL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABSI BREAKDOWN
97d in phase · OBV NEUTRAL
Current IV 169.1%
IV Percentile 15th %ile
Put/Call OI Skew 0.57x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABSI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABCL CONSOLIDATION
34d in phase · OBV NEUTRAL
Current IV 80.8%
IV Percentile 25th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABSI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and -9108.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABCL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8B market capitalization and -1550.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABSI vs ABCL Key Questions & Quantitative Answers

As of Nov 16, 2026, AbCellera Biologics Inc. Common Shares (ABCL) is the stronger overall head-to-head candidate over Absci Corporation (ABSI) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ABSI carries a Unified Composite Score of 37.5/100 (SELL) at $7.72 (N/M Forward P/E, -9108.3% operating margin), whereas ABCL carries 60.7/100 (BUY) at $11.19 (27.6x Forward P/E, -1550.0% operating margin). Growth vs. Quality Trade-Off: ABCL earns the overall head-to-head edge with a stronger Unified Composite Score (60.7/100 BUY vs. ABSI 37.5/100 SELL) and 2.31β · 87% Vol risk profile, whereas ABSI leads top-line expansion (-19.6% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ABSI is currently in a Breakdown options structure phase (RSI 39.3); meanwhile ABCL trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 44.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABCL leads the Growth & Scale pillar: ABSI posts -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin), compared with ABCL at -76.3% YoY revenue growth and +45.9% YoY earnings growth on $66M TTM revenue (N/A gross margin, -1550.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), ABSI cumulative revenue shifted +0.0% while ABCL shifted +700.0%. In operating R&D and SG&A reinvestment, ABSI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ABCL.

ABCL screens cheaper on headline valuation multiples. ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ABCL trades at 27.6x Forward P/E, 27.6x Trailing P/E, N/M PEG, and 56.9x EV/Revenue (-49.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABSI (-58.6% ROE) versus ABCL (-17.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ABSI carries 169.1% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.31β · 126% Vol realized risk). By comparison, ABCL carries 80.8% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.31β · 87% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.